Antibody Drug Conjugates Market Witnesses High Growth Owing to Advancement in Targeted Cancer Therapy
Antibody Drug Conjugates Market Witnesses High Growth Owing to Advancement in Targeted Cancer Therapy
Blog Article
ADCs function by selectively delivering cytotoxic, or cell-killing, agents to tumors while minimizing toxicity to normal tissues. This targeted approach is known to increase efficacy without exacerbating toxicity.
The global antibody drug conjugates market is estimated to be valued at US$ 7.02 Bn in 2024 and is expected to exhibit a CAGR of 14.2% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Antibody Drug Conjugates market are AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, copyright, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
The key opportunities in the market include increasing demand for targeted cancer therapies and rising R&D investments by various pharmaceutical companies in developing ADC drugs. Technological advancements such as site-specific conjugation of drugs to antibodies help in overcoming challenges related to conventional drug conjugation methods and improve cytotoxic potential of ADC drugs.
Market Drivers
The rising demand for targeted cancer therapies, growing R&D expenditure by pharmaceutical and biopharmaceutical companies, increasing focus on the development of ADC drugs with novel linkers and warheads, and technological advancements in antibody conjugation techniques are some of the key factors expected to drive the growth of the global antibody drug conjugates market during the forecast period. With increasing investments and improving technologies, ADCs are poised to play a crucial role in the management of various cancer types in the coming years.
The Antibody Drug Conjugates Market Size faces several challenges that hinder its growth. One of the major challenges is the complexity involved in the development and manufacturing of ADC drugs. Linkers and payloads used in these drugs are highly complex molecules and even minor changes can affect their efficacy and safety. Developing the right combination of antibody, linker and cytotoxic agent is challenging.
Another big challenge is the heterogeneity of ADC drugs. During manufacturing, ADC drugs contain mixtures of payloads attached at different sites and stoichiometries, making their characterization difficult. Ensuring consistency and reproducibility across different batches poses difficulties.
The high cost of development is also a major roadblock. Developing an ADC drug requires expertise across multiple disciplines like molecular biology, protein engineering and medicinal chemistry. This extensive R&D coupled with challenges in manufacturing drives up costs significantly. Commercializing such an expensive drug is risky for companies.
Many ADC drugs also face pharmacological challenges. They have shorter half-lives compared to conventional drugs requiring higher and more frequent dosing. Payloads can be released prematurely in the body before reaching the tumor site reducing efficacy. Ensuring stability of the drug conjugate until it reaches the target site is difficult to achieve.
Toxicities resulting from the potent payloads also pose safety concerns. Non-specific release of cytotoxic agents leads to off-target effects damaging healthy tissues. Developing toxins that are selective only towards tumor cells while avoiding healthy tissues is a major scientific challenge.
These complexities and risks associated with ADC development lengthen the time taken to get these drugs through clinical trials and gain regulatory approvals. Overcoming the scientific and technical barriers is crucial for the growth of this innovative class of oncology drugs.
Get more insights on - Antibody Drug Conjugates Market
Explore More Related Article on – Immunotherapy Drugs Market
Get More Insights—Access the Report in the Language that Resonates with You.
About Author:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)
Report this page